<DOC>
	<DOC>NCT01562574</DOC>
	<brief_summary>This trial is conducted in Oceania. The aim of this trial is to investigate the efficacy of activated recombinant human factor VII and standard treatment compared with standard haemostatic replacement therapy in cardiopulmonary bypass (CPB) surgery for paediatric congenital heart disease.</brief_summary>
	<brief_title>Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects, Congenital</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Signed informed consent obtained from parent or legal guardian before any trialrelated activities. Trialrelated activities are any procedure that would not have been performed during normal management of the subject Children with complex congenital heart disease requiring corrective surgery with cardiopulmonary bypass (CPB) Congenital heart disease that does not require CPB surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>